CliffBio
small molecule

EOHILIA

BUDESONIDE

Loss of exclusivityJanuary 2039latest FDA-listed patent expiry
CompanyTAKEDA PHARMACEUTICALS USA INC

Drug detail

Brand nameEOHILIA
Active ingredientBUDESONIDE
Strength2MG/10ML
Dosage formSUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 2024
Marketing statusRX

Listed patents

PatentExpiresType
11564934January 2039use U-3820
11260064January 2039product
8324192August 2029use U-3820
9050368August 2029product
10293052November 2028product
11357859November 2028use U-3820
11197822November 2026product
8975243November 2026use U-3820
8497258November 2026use U-3820
9119863November 2026use U-3820
11413296November 2026product
8679545November 2026product

Regulatory exclusivity

CodeExpires
ODE-466February 2031
NPFebruary 2027

More from TAKEDA PHARMACEUTICALS USA INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

EOHILIA patent cliff — loss of exclusivity January 2039 | CliffBio